The sebetralstat Early Access Program (EAP) provides early access to the investigational medicinal product (IMP) sebetralstat to eligible and approved Hereditary Angioedema (HAE) pediatric (ages 2-11) post-trial and naïve patients for the on-demand treatment of angioedema attacks where the treating Physician determines they might benefit from this treatment.
Protocol Amendment History
4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2025-10-08; most recent amendment 2026-07-22.